1	Cost minimization analysis of treatments for metastatic HER2-
2	positive breast cancer: Fixed-Dose combination of pertuzumab
3	and trastuzumab for subcutaneous injections
4	
5	Cost minimization for HER2-positive breast cancer
6	
7	Miguel Figallo ^{1*} , María F. Delgado ² , Mauricio Gonzalez ¹ , Adrián Arenas ³
8	
9	¹ APOYO Consultoría, Lima, Peru
10	² London School of Economics, London, UK
11	³ Universidad de Piura, Lima, Perú
12	
13	
14	* Corresponding author
15	E-mail: mfigallo@apoyoconsultoria.com (MF)
16	
17	https://orcid.org/0009-0008-1308-8677

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

Abstract

19 The main objective of this study is to determine whether the employment of fixed-dose combination of pertuzumab and trastuzumab for subcutaneous injection (or Phesgo) to 20 21 treat metastatic HER2-positive breast cancer patients would minimize costs compared to the traditional treatment of separate intravenous doses of pertuzumab and 22 trastuzumab in Peru. To achieve this, we used EsSalud (the social security health 23 insurance) data and assessed it through a mixed strategy, which consisted of a 24 quantitative and a qualitative approach. The first one aimed to calculate the direct (non-25 drug consumables, drugs, and healthcare professionals) and indirect costs of both 26 27 treatments to develop a comparison, whilst the second aimed to validate information and 28 internalize the procedure in an EsSalud context.

29 Overall, we found that the usage of Phesgo would be cost saving in EsSalud's context. 30 Specifically, we found three main insights. Firstly, the savings produced from switching from the traditional intravenous treatment to the subcutaneous one would allow EsSalud 31 32 to afford full annual costs of 2 additional treatments, but without increasing their budget. 33 This would cover 7% of the gap of 29 patients who do not have access to full treatment. 34 Secondly, the result of a univariate sensitivity analysis in this work indicates that the price of Phesgo would have to increase by 16% so that both treatments cost the same. Thirdly, 35 to increase the number of patients, the intravenous treatment would have to be totally 36 37 replace by the Phesgo treatment, since the use of the latter requires less personnel and 38 infrastructure.

Introduction

In Peru, breast cancer is the second most common neoplasm, affecting mainly women 40 over 34 years of age. By 2022, 3,166 new cases of breast cancer were reported in Peru, 41 42 18% more than the previous year [1]. Within the subtypes of breast cancer, HER2positive is a type of breast cancer whose cells have higher levels of the HER2 protein, 43 44 which is present on the outside of all breast cells and promotes their growth [2]. 45 According to the Peruvian Social Security (EsSalud), this type represents about 25% of 46 all cases of breast cancer (EsSalud, 2017) and it is related with poor prognosis and 47 aggressiveness.

The standard treatment applied by EsSalud for this type of neoplasm consists of the application of anti-HER2 medications —pertuzumab and trastuzumab— which are infused separately into a vein (IV). According to the in-depth interviews, a rough approximation of 30% of patients with HER2-positive metastatic breast cancer are not receiving the pertuzumab and trastuzumab treatment regime. This dual treatment scheme for patients with HER2-positive breast cancer in metastatic stage who have not received previous systemic therapy was approved by Essalud in 2017 [3].

55 Besides, the Peruvian Ministry of Health (Minsa) approved the treatment in March of 2023, but indicating that it is not cost-effective, and that its purchase should be given 56 through what they call "differentiated mechanisms of acquisition". The resolution argued 57 that the incremental cost per year of life gained (YLG) in a patient using pertuzumab was 58 59 above the cost-effectiveness threshold established by Minsa (16). Moreover, this 60 decision relied on the results of the CLEOPATRA study, which was conducted between 2010 and 2018, and sought to analyze the efficacy of the addition of pertuzumab to the 61 62 traditional treatment of docetaxel and trastuzumab for patients with metastatic HER2-63 positive breast cancer. The study showcased an improvement in progression-free and overall survival (OS), with a median of 57.1 months in the pertuzumab group and 40.8 64

65 months in the placebo group [4]. The difference in the overall survival is strongly 66 significant, as it has a p-value of 0.0008.

The IV administration has major disadvantages, mainly on the patient's side, in terms of the large number of hours they must spend at the healthcare facility, as well as the considerable discomfort its application entails. Similarly, being a long treatment that requires many supplies, it generates significant costs for the healthcare facility, both in the price of consumables and in the time spent by healthcare professionals.

The fixed-dose combination of pertuzumab and trastuzumab for subcutaneous injection (PH FDC SC; and Phesgo as brand name) has come up as an alternative treatment method for metastatic HER2-positive breast cancer. This treatment utilizes the same drugs as in the standard of care —pertuzumab and trastuzumab—, however, they are administered via a subcutaneous injection (SC), which adds an enzyme called hyaluronidase.

The literature surrounding this topic has previously addressed the advantages of employing the pertuzumab and trastuzumab combined treatment, additional to the cost minimization due to transitioning from the IV to the SC treatment.

Regarding the advantages of Phesgo, works such as the FeDeriCa study, have shown that this treatment has the same level of efficacy and offers key advantages when compared to the IV treatment (IV) [5]. Additionally, the PHranceSCa study, showcases that breast cancer patients prefer the subcutaneous treatment over the IV scheme [6]. That is because it reduces clinic time and enhances comfort during administration.

Hence, based on the literature, the following benefits are generated by the application ofPhesgo:

On the patient's side, it presents much shorter administration and observation
 times, which has reduced the impact of undergoing cancer treatment on their

daily lives, as it increases the amount of time they can devote to productive
 activities, leisure time, and family time, among others. Besides, the application of
 SC treatment is considerably less intrusive and uncomfortable.

On the healthcare facility side, it has been possible to release capacity in the
 chemotherapy units for other treatments, significantly reduce intravenous
 compounding costs, and reduce wastage. On the other hand, it saves costs for
 the healthcare provider, using less active employee time and reducing non-drug
 consumable costs.

98 Now, with regards to the cost minimization of transitioning to the SC treatment, we 99 identified three key studies that have shed light on the topic at hand. Firstly, one 100 approached the cost minimization through the reduction of non-drug costs and other 101 related economic costs such as HCP (Health Care Professional) time and patient time 102 [7]. Secondly, other used a Time and motion (T&M) methodology to also estimate the 103 time cost of both the IV and SC treatments, and the direct and indirect costs associated 104 with these [8]. It concluded that a transition to SC in a Spanish context would significantly reduce direct costs in 979.60 euro per full cycle treatment as well as reduce the time 105 106 used, which minimized the loss of productivity. Thirdly, in a similar study conducted in Cuba, it was found that the subcutaneous treatment proved to minimize costs with 107 108 respect to the intravenous treatment even when its price was increased by 30% [9]. This 109 result differs from what will be shown afterwards because the characteristics of both 110 healthcare systems have critical differences.

On the one hand, the prices of the IV and SC anti-Her2 drugs are considerably higher than what we are considering. In fact, almost all the savings that study found were explained by that source. On the other hand, the non-drug consumables that are considered in the Cuban study are considerably cheaper than what is considered in this study, which discards non-drug consumables as a relevant source of savings. Finally,

the Cuban estimation for IV procedures duration is higher than ours, which explains why

their time savings are higher than ours.

As it has been shown, Phesgo appears to have similar efficacy and safety profile when compared to the IV scheme, making it reasonable to determine whether it minimizes the treatment costs in EsSalud and in which magnitude. Hence, this study aims to identify savings opportunities for both patients and healthcare facilities, so that the public expenses execution is optimized without deterring the quality of attention. This is particularly important in the context of high limitations and deficiencies present in the Peruvian healthcare system.

Materials and methods

126 Data used

We use public information from the Peruvian social health security. We use the followingsources of data:

129 Hospital administrative documents: We retrieved the annual salaries of nurses and 130 pharmaceutical chemists and accessed the list of EsSalud strategic purchases [10]. The 131 latter list included the prices and specific characteristics (size, type, etc.) of drugs, non-132 drug consumables, and medical equipment for cancer treatment. Finally, the pertuzumab and trastuzumab monthly consumption series and the number of chemotherapy couches 133 were provided by EsSalud. The latter pieces of information were at the hospital level and 134 allowed us to estimate both the number of treated patients and the nationwide attention 135 136 capacity.

Clinical practice guidelines: The HER2-positive metastatic and non-metastatic breast cancer clinical practice guidelines contain the step-by-step process and medication needed for the IV treatment [11]. This information served as an input for the in-depth interviews that were followingly conducted.

141 Methodology

The study followed a mixed strategy, which considered both a quantitative and qualitative approach. Under the quantitative approach, following recent contributions, we considered a time horizon of a full year and a singular patient approach. Given that the treatment is applied every 21 days, we estimate the cost of a total of 18 cycles or doses per year, which is consistent with previous contributions [9] [7] [8]. Accordingly, for that period of treatment, we defined 3 different stages for HER2-positive metastatic breast cancer:

i. Loading (1 cycle): It refers to the initial cycle of each treatment, the following
cycles are known as maintenance. Chemotherapy is applied in this cycle along
with trastuzumab and pertuzumab by IV infusion separately or both together by
Phesgo injection subcutaneously.

ii. Maintenance with chemotherapy (5 cycles): For the first 5 maintenance cycles,
chemotherapy must be applied, along with pertuzumab and trastuzumab.

155 iii. Maintenance with no chemotherapy (12 cycles): For the rest of the 12
156 maintenance cycles, the treatment is with trastuzumab and pertuzumab. No
157 chemotherapy is required.

For the calculation of costs, we considered the direct and indirect costs. For direct costs, the following three categories were included: (i) non-drug consumables, (ii) drugs, and (iii) healthcare professionals. In the case of indirect costs, we considered an estimation of the value of time of patients to get the savings or losses attributable to the change in the treatment scheme. This calculation used as an input the statistic value of life [12]. Further methodological details of this estimation are provided in Section 5.

164 On the qualitative side, two in-depth interviews with key EsSalud personnel were carried 165 out. The first one covered the treatment room procedures whilst the second one provided

a closer approximation to the oncology mixing room procedures, both executed
simultaneously. Both interviews validated information such as: (i) the duration of each
identified procedure, and (ii) the specific inputs needed for the execution of each
procedure. Those pieces of information were provided as ranks, which let us internalize
the variability that time and quantities can suffer when administrating the treatment in the
EsSalud context.

172 Treatment schemes characterization

The most widely used targeted anti-HER2 treatment is intravenous pertuzumab and trastuzumab (IV). In the case of the Peruvian health system, chemotherapy sessions are applied throughout the treatment cycle [13]. Based on local clinical guidelines and on relevant literature, validated through the interviews with the healthcare professionals, an orderly structure of the steps of the IV treatment for HER2-positive metastatic breast cancer applied by EsSalud was constructed. In addition, the structure for SC treatment was recovered based on the literature reviewed. They are both illustrated below in Fig 1.

Fig 1. Stages in IV and SC treatment schemes. *Note: Mixing room preparation procedures occur simultaneously with the previous ones (cannulation, hydration, premedication).*

183 Results

184 Cost minimization

We obtained all the costs involved in the treatment of breast cancer, both for the healthcare facility and for the patient, to make an exhaustive comparison between the total costs that each treatment scheme entails. In that sense, the costs of a year of treatment in terms of drug and non-drug consumables, lost staff capacity and patient hours are also calculated. This section compares the total annual costs of IV and SC treatments and highlights the savings that the SC scheme represents over IV for the

following categories: (i) non-drug consumables, (ii) healthcare professionals, (iii) indirect
costs, and (iv) drug costs.

From previous contributions [7], one can find that the non-drug saving in the United States is of 75%, which is mainly driven by chair time costs (62% of total savings, which equals 75% in this study). For our case, in Fig 2, the total annual costs per patient for each category, excluding drug costs, are shown for both the IV and SC schemes, and the estimated difference between the two is calculated. It is shown that the total annual savings per patient is US\$ 5,395, which represents a reduction of approximately 64% of the cost of the IV scheme without including drug costs.

200 It is worth stressing, however, that this estimation does not represent the overall saving 201 of Phesgo, nor does it represent how much can the price of Phesgo be increased while 202 still minimizing costs. The correct interpretation to this estimation contemplates that this 203 is the savings in non-drug costs.

Fig 2. Annual cost per patient without drug costs, IV vs SC (US\$).

Followingly, in Table 1 a breakdown of each category including drug costs is made to analyze in detail the total savings per patient for each of them and which are the main sources —materials or procedures— through which these savings are perceived. A purchase period for nun-drug consumables and drugs is considered between September 5 and 7, 2022.

210

Table 1. Annual savings per category (US\$)

Category Savings per patient		Savings per patient	Main sources of savings		
Direct	costs				
1	Healthcare professionals	US\$ 1314	 Preparation in mixing room (US\$ 394) Administration of monoclonal antibodies (US\$ 272) Hydration (US\$ 227) Monitoring after monoclonal antibodies (US\$ 201) 		

2	Non-drug consumables (materials)	US\$ 999	 Short double-lumen catheter (US\$ 812) Venoclysis equipment (US\$ 91) Trifurcated equipment (US\$ 68)
3	Drug costs	US\$ 332	 Monoclonal antibodies (US\$ 306) Sodium chloride 250 cc (US\$ 15) Sodium chloride 1 L (US\$ 7)
Indire	ect costs		
4	Indirect costs	US\$ 3,082	 Administration of monoclonal antibodies (US\$ 911) Hydration (US\$ 762) Monitoring after monoclonal antibodies (US\$ 673) Vein cleaning (US\$ 355)
Note:	This list is not exhaustive	e. It only considers the	main sources of savings. Hence, the sum of the sources

of savings will not necessarily equal the savings per patient shown.

213 Indirect costs

211

For the estimation of indirect costs, we considered the patients' loss of productivity generated by the time in clinic (waiting and treatment time). To reach that estimation, we calculated both the time in clinic and the value of patients' time. The following steps were followed:

- For estimating the time in clinic: Based on the clinical practice guidelines and
 the in-depth interviews, we calculated the total time spent in clinic by each patient
 in each treatment cycle.
- For the value of patients' time: We took advantage of the statistic value of life
 [12] which provides a vector of statistic values for each year of life going from 0
 to 99. These calculations were based on the human capital method, which means
 that the values of life that he provided represent the total productivity of a
 representative individual at each year of age.

By taking advantage of the number of ambulatory attentions related to breast cancer available at the REUNIS database, we obtained weights for estimating an average statistic value of life adjusted to the representative breast cancer patient. After obtaining this weighted average, we were able to monetize the time saved as a consequence of the use of Phesgo, which yielded a total saving per patient of US\$3,082. This saving represents a reduction of 63% when compared to the IV scheme.

The main savings are perceived in the stages of: (i) administration of monoclonal antibodies, (ii) hydration, (iii) monitoring after monoclonal antibodies and (iv) vein cleansing, which account for 88% of the total savings in this category. The reasons behind the savings are the same as for the healthcare professional's category; however, in this case, the preparation in mixing room does not come into play since this stage does not require patient time.

239 Healthcare professionals

Regarding the time saved by the healthcare professionals, the time spent in each procedure of both treatments was collected from the interviews and clinical guidelines. Based on those inputs, the nurse-minute costs were calculated (US\$ 0.25). As a result, a total saving of \$1,314 in healthcare professionals' costs was estimated. This represents a reduction of 66% with respect to the IV scheme.

The main savings come from the stages of preparation in the mixing room, followed by administration of monoclonal antibodies, hydration and monitoring after monoclonal antibodies. These savings collectively represent 83% of the total savings in this category. Since in the SC treatment there are several procedures that are not applied after the first 6 cycles, as can be seen in Fig 1. In addition, other procedures require nurses to dedicate less time to the treatment, such as the administration and monitoring of pertuzumab and trastuzumab.

- 252 Table 2 shows the savings in terms of hours of healthcare professionals in the SC
- scheme compared to the IV scheme. 253

254 Table 2. Hours spent by healthcare professionals for the treatment of a single patient, by stage per year. 255

Stage of treatment	IV	SC	Savings
Loading (1 cycle)	7.5	4.6	39%
Maintenance with chemotherapy (5 cycles)	30	21.5	28%
Maintenance with no chemotherapy (12 cycles)	60	10	83%
Total hours spent per year	97.5	36.1	63%

Total hours spent per year | 97.5 | 36.1 | ⁰³% **Note:** For both treatment schemes, a constant initial evaluation period of 30 minutes per cycle is considered 256

257 in the total hours spent.

258 Although these savings do not directly reduce the budget, they represent a release of human resources capacity for the attention of other patients. Furthermore, this will 259 260 alleviate the overburden and distress that the healthcare personnel currently go through. which will in turn improve the overall quality of the service. The benefits of this attention 261 capacity release are addressed afterwards. 262

Non-drug consumables 263

264 Regarding the non-drug consumables, the main inputs for the analysis were: (i) prices, 265 which were obtained from the EsSalud's catalogs; (ii) quantities required for each 266 treatment scheme, which were collected from clinical guidelines and interviews. As a result of the analysis, a total saving of US\$999 in non-drug consumables per patient was 267 estimated. This represents a reduction of 62% with respect to the IV scheme. 268

269 The main saving comes from the reduction in the use of: (i) short double-lumen catheter, 270 (ii) venoclysis equipment, and (iii) trifurcated equipment. The savings generated by the 271 disuse of these three elements represent 97% of the total saving in this category, this is 272 because in the SC treatment these instruments are used only in the first 6 cycles when 273 chemotherapy is applied, while in the IV treatment they are used in all cycles. Minor

savings are also perceived because in the IV treatment additional consumables are used
in the mixing room for the preparation of pertuzumab and trastuzumab, which do not
apply to the SC treatment.

A table is presented showing the annual costs in non-drug consumables represented by the inputs of the IV and SC treatment schemes. In that table, considerable savings can

be observed in the SC scheme with respect to the IV scheme (Table 3).

As Table 3 shows, the savings are not uniformly distributed across the defined stages.

This is so because, in the SC treatment scheme, the catheter is only used in the first 6

282 cycles when chemotherapy is applied, whilst in the IV scheme, it is used throughout the

283 entire treatment. In addition, since several stages of the SC scheme are only applied in

the chemotherapy cycles, as shown in Fig 1, the healthcare facility experiences

significant savings in terms of non-drug consumables.

			First 6 cyc	cles		Last 12	cycles	Total	Total
	Unit cost	Co	sts	Savings		Costs	Savings	Savings	Savings
(i) Non-drug consumables		IV	SC	IV-SC	IV	SC	IV-SC	IV-SC	%
Short double lumen catheter 2 FR	97	406	406	-	812	-	812	812	67%
Venoclysis equipment	8	45	45	-	91	-	91	91	67%
Trifurcated equipment	6	34	34	-	68	-	68	68	67%
PORT catheter needle	5	9	9	-	17	-	17	17	67%
20 cc syringe	0	2	1	1	3	-	3	4	86%
Tegaderm 6x7	0	2	2	-	4	-	4	4	67%
18 X 1 1/2" needle	0	1	0	0	1	-	1	2	79%
10 cc syringe	0	1	1	-	1	-	1	1	67%
5 cc syringe	0	0	1	0	1	-	1	1	50%
20 X 1 1/2" needle	0	0	0	0	-	-	-	0	(233%)
22 X 1 1/2" needle	0	0	0	-	0	-	0	0	67%
PORT catheter	287	86	86	-	-	-	-	-	-
Infusion line	5	32	32	-	-	-	-	-	-
Package of gauze	0	0	0	-	1	1	-	-	-
Total	408	618	617	1	999	1	998	999	100%
Note: All numbers are round	led to the near	est integer. P	rices were ret	rieved from EsSalu	ud strategic purc	hases catalog.	We use the average e	xchange rate fo	r the month of
December 2022	reported	by	the	Central	Reserve	Bank	of Peru.	(PEN/US\$:	3.829).

Table 3. Annual costs and savings from non-drug consumables (US\$)

289 **Drug costs**

The use of Phesgo in this treatment also reduces drug costs. This includes the costs and quantity of medicines used in both treatment schemes: pertuzumab, trastuzumab, docetaxel, sodium chloride, and ondansetron, among others. Even under the assumption that Phesgo price is equivalent to the sum of prices available of pertuzumab and biosimilar trastuzumab, there is a reduction of US\$ 332. This represents a saving of less than 1% on drug costs. In Table 4 the price of the main drugs applied in treatments is shown.

297

Table 4. Price of main drugs (US\$)

Drugs	Price
Pertuzumab 420 mg/14 mL	1,941
Trastuzuab 21 mg/mL x 20 mL (with diluent)	186
Phesgo – Loading (1200 mg of Pertuzumab)	3,192
Phesgo – Maintenance (600 mg of Pertuzumab)	2,128

298

299 Table 5 showcases that the main savings come from the application of monoclonal 300 antibodies. On one hand, particularly, from the extra trastuzumab and pertuzumab that 301 is required by the IV scheme when reconstituting the drugs. It is worth mentioning that 302 the trastuzumab vial purchased by EsSalud is standardized and contains 21 mg/ml x 20 303 ml. Since the trastuzumab dose depends on the weight of the patient, more or less than one vial may be required. This parameter was estimated considering a women average 304 weight of 57 kg [14]. Specifically, for the loading cycle, 8mg/kg are applied; for the 305 306 maintenance cycles, 6 mg/kg are applied. Having a standardized vial of 420 mg and considering the average weight, 456 mg (1.09 vials) would be necessary for the loading 307 308 cycle, whilst 342 mg (0.81 vials) would be necessary for maintenance cycles.

309 On the other hand, Phesgo provides a fixed dose, and its price is equal to the sum of the 310 prices of pertuzumab and trastuzumab, except for the loading cycle, where the price of

311 Phesgo is multiplied by a factor of 1.5 (this is consistent with its current global pricing 312 strategy). Hence, spending on a fixed dose of SC results cheaper than spending on the 313 alternative, which may require additional expenditures on trastuzumab depending on the 314 patient's weight. As it is not plausible to expect a uniform distribution for patients' weight, there is a variable leftover of trastuzumab in the IV scheme. Our model considers an 315 ideal case in which this leftover is never wasted. However, this assumption stresses the 316 results because it reduces the drug costs of the IV scheme, which underestimates the 317 318 savings generated by the adoption of Phesgo. For every 1% of leftover wasted, savings increase in US\$ 26, which represents 8% of the estimated drug costs savings. Under the 319 extreme case in which the whole leftover is wasted, savings in drug costs would equal 320 321 US\$ 589.

322 However, the above-mentioned savings are concentrated in the first 6 cycles of 323 treatment, and, particularly in the loading cycle. Considering an average-weight patient, 324 the first cycle of the IV scheme requires the use of two vials of pertuzumab, which would cost US\$ 3,882, and 456 mg of trastuzumab which would cost US\$ 203. Thus, the 325 326 application of monoclonal antibodies under the IV scheme requires an expenditure of 327 US\$ 4,085 only for the loading cycle. In comparison, the SC scheme takes advantage of a fixed loading dose of Phesgo, which costs US\$ 3,192, which implies a saving of US\$ 328 329 893 only for the first cycle.

330 The following cycles (2-18) showcase minor de-savings, which are visible in the first row 331 of Table 5. The reason behind those losses is the assumption of no waste of leftovers. 332 As it is detailed in footnote 10, the use of this assumption underestimates the 333 pharmacological savings of Phesgo because it considers an ideal setting in which the 334 content of each vial of trastuzumab is perfectly distributed and consumed. 335 Notwithstanding the above, the pharmacological savings resist this extreme scenario, 336 which strengthens the savings capacity of Phesgo. Fig 3 shows a breakdown of all 337 savings and de-savings received in all 18 cycles in one year divided by stage.

Fig 3. Savings and de-savings for all 18 cycles in drug costs of using Phesgo 338

(US\$). 339

		First 6 cycles		cles	Last 12 cycles			Total	Total
	Unit cost	C	osts	Savings	С	osts	Savings	Savings	Savings
(i) Drug consumables		IV	SC ^{1/}	IV-SC	IV	SC ^{1/}	IV-SC	IV-SC	%
Dual anti Her2 drugs	2,128	14,552	13,830	722	25,117	25,533	-416	306	0%
Sodium chloride 250cc	0	8	3	5	10	-	10	15	83%
Sodium chloride 1L	1	4	4	-	7	-	7	7	64%
Ondansetrón 8 mg	0	2	2	-	3	-	3	3	60%
Dexamethasone 2 mg / ml X 2 ml	0	0	0	-	1	-	1	1	100%
Docetaxel	16	98	98	-	-	-	-	-	-
Clorphenamine 10 mg / ml X 1 ml	0	1	1	-	-	-	-	-	-
Ranitidine 25 mg / ml X 2 ml	0	0	0	-	-	-	-	-	-
Total	2,145	14,665	13,938	727	25,138	25,533	-395	332	100%

Table 5. Annual costs and savings from drugs (US\$)

341

342 Note: All numbers are rounded to the nearest integer. Prices were retrieved from EsSalud strategic purchases catalog. We use the average exchange rate for the month of

343 December 2022 reported by the Central Reserve Bank of Peru. (PEN/US\$: 3.829). 1/ The SC treatment is referred to Phesgo, while the IV treatment refers to the intravenous 344 administration of pertuzumab and trastuzumab.

345 Payer's costs

Two steps were followed to estimate the budgetary impact for the payer: (i) estimation of the number of patients treated with complete and incomplete treatment and (ii) monetary and non-monetary savings estimation, which we proceed to detail below.

349 Estimated number of patients

350 The number of patients was estimated through two different approaches. The first approach (top-down) consisted of taking the total cases presented by GLOBOCAN 2020 351 352 of breast cancer in Peru (22,486) and disaggregating them progressively by multiplying 353 it by the following probabilities: (i) suffering HER2-positive breast cancer (25-30%), (ii) suffering metastatic breast cancer (9%) reported by FISSAL, and (iii) being treated by 354 355 EsSalud (18%, estimated by considering the total breast cancer patients attended by 356 Minsa, EsSalud, and INEN). Fig 4 shows each step and intermediate result of this 357 estimation. As it is shown, we concluded that EsSalud currently treats 100 HER2-positive 358 patients in the metastatic stage.

Additionally, based on the in-depth interviews with key EsSalud personnel, an approximate of 30% of HER2-positive metastatic breast cancer are not treated with pertuzumab, despite requiring it. By considering this proportion of patients who do not have access to full treatment, we calculate that there is a gap of 30 patients who are not receiving proper treatment.

364 Fig 4. Top-down approach.

The second approach (*bottom-up*) consisted of obtaining the expected monthly consumption of pertuzumab for a single patient. For that to happen, we used the probability of being a new patient (31%) by obtaining the 5-year prevalence of breast cancer (22,486) and the number of new cases per year (6,860). This probability allowed us to calculate an expected monthly consumption of 1.31 vials, considering that the

370 patient receives each dose once every month (although medical indication states that 371 the dose must be applied every 21 days, we considered the considerable lags in 372 administration). Therefore, this calculation was the result of the weighted sum of 1 vial 373 consumed by a maintenance patient and 2 vials consumed by a new patient. Rescaling this value to an annual time frame yields an expected consumption of 15.66 per patient. 374 Then, the total pertuzumab consumption of each healthcare facility was divided by the 375 376 expected consumption per patient to get an estimate of the number of patients, which 377 we calculate at 65.

Nonetheless, as this calculation took the consumption of pertuzumab as an input, we rescaled it to get the full universe of HER2-positive metastatic breast cancer. Specifically, we followed the fact that there is a gap of 30% who do not receive full treatment, which means that this 30% only receive trastuzumab.

This exercise allowed us to estimate that there was a full universe of 93 patients treated with either complete or incomplete treatment schemes, which yields a gap of 28 patients that do not have access to full treatment. Fig 5 shows each step and intermediate result of the described approach.

Fig 5. Bottom-up approach. Notes:1/ Total number of vials of pertuzumab consumed in EsSalud during 2022. Recovered from the list of purchases of strategic goods. 2/ The estimation of the gap follows the fact that the number of patients with complete treatment are the 70% of the full universe of attended patients. Source: In-depth interviews.

Based on the above-described methodologies, it is estimated that the average gap of patients who do not access to full treatment is of 29, which, according to the information recovered in the interviews, can be explained by the restrictions and resource limitations that challenge the healthcare system. Table 6 shows the estimation, under each approach, of: (i) total attended patients, (ii) patients who access to full treatment

395 (pertuzumab + trastuzumab), and (iii) gap of patients who do not have access to full

treatment. In addition, it showcases the average estimates.

397

Table 6. Summary table - Number of patients estimation

Approach	Attended patients	Full treatment	Access gap
Top-down	100	70	30
Bottom-up	93	65	28
Average	97	68	29

398 Monetary and non-monetary savings for EsSalud

Based on the above estimates, the total EsSalud monetary savings in direct costs at the 399 400 national level are US\$ 90,535. This estimation considers both approaches' average 401 estimate of patients who currently access full treatment in EsSalud (68), it is calculated 402 that the social security would save US\$ 67,947 in non-drug consumables per year by 403 adopting Phesgo. This represents 62% of what the social security system spends each 404 year on consumables needed for the treatment of HER2-positive metastatic breast 405 cancer. Additionally, the use of Phesgo generates savings in drug costs, as the SC treatment demands lower uses of premedication, hydration, and reconstitution. These 406 407 savings are of US\$ 22,588 per year. Moreover, a sensitivity analysis was performed, which showcased that an increase of 0.84% in the price of Phesgo is required for the 408 409 savings in drug costs to be zero, and an increase of 3.38% is required for the savings in 410 direct costs —which includes drug costs and non-drug consumables costs— to be zero.

Moreover, the adoption of the subcutaneous treatment would also have non-monetary savings in terms of (i) the availability of nurses and (ii) the release of chemotherapy chairs use time. Since the adoption of Phesgo generates an annual saving of 61 hours per patient and we estimate 68 currently attended patients, it is calculated that there will be a release of more than 4,000 nursing hours and chemotherapy chairs use time. As we estimate that 97 hours are required to attend a patient through a whole year under an IV scheme, we calculate that the freeing up of capacity would allow the attention of

41 additional IV patients per year without incurring on more investment costs than the
needed to be able to close the access gap of 29 HER2-positive metastatic breast cancer
patients, as specified in Table 6.

421 **Robustness checks**

To stress our results, several robustness checks were performed. In particular, we ran sensitivity analyses for two key variables: (i) price of Phesgo and (ii) price of Pertuzumab. Regarding the first test, Fig 6 provides three different scenarios that allow us to tell how total savings for a single patient are affected by the price of the SC treatment. Those scenarios are: (i) baseline, (ii) 5% increase in the price of Phesgo, and (iii) 5% decrease in the price of Ph esgo without adjusting the price of pertuzumab and trastuzumab. Table 7 rescales the resulting savings for the payer (EsSalud) under each provided scenario.

429 A 5% increase in the price of Phesgo would reduce total savings in 34%, going from US\$ 5,727 to US\$ 3,759 per patient. This result features a de-savings of US\$ 1,636 per 430 431 patient in drug costs, which runs up to US\$ 111,246 when rescaling it to the full universe of attended patients. However, what is more important is that, despite bearing this loss, 432 433 total savings are positive. That is because we are not only considering direct savings for 434 the payer –which are, in this case, negative and detailed in Table 7–, but savings in healthcare professionals and patients time, whose monetary equivalents are featured in 435 436 Fig 6.

Besides, we find an expansion of savings when considering a 5% decrease in the price of Phesgo. Annual savings in drug costs go up to US\$ 2,300 per patient, which is equivalent to a total saving of US\$ 156,421 when rescaling it to the full social security system. This would have two strong benefits: (i) from a social perspective, savings experiment an increase of 34%, and (ii) from a payer's perspective, savings experiment an increase of 148%.

443 Fig 6. Price of Phesgo sensitivity analysis for the annual savings of a single patient

(US\$). Note: For the construction of each scenario, every other variable is kept constant. 444

- The savings here portrait consider both the experimented by patients and the payer in a 445
- 446 timeframe of a full year.

447 Table 7. Price of Phesgo sensitivity analysis for the annual savings of EsSalud 448 (US\$)

	Baseline	+5%	-5%
Non-drug consumables	67,947	67,947	67,947
Drugs	22,588	(111,246)	156,421
Monetary savings for the payer	90,534	(43,299)	224,368
Note: The savings here portrait consider a univ	verse of 68 patients i	n the social security h	ealthcare system

449 450 (EsSalud). This number of patients follows Section 6, so it represents the estimated number of HER2-451 positive metastatic breast cancer treated with pertuzumab and trastuzumab.

452 As to the sensitivity analysis with respect to the price of pertuzumab, Fig 7 shows three 453 different tests that were conducted. Each of these tests consisted in the progressive addition of savings boxes with the aim of finding the reduction in the price of pertuzumab 454 455 that offsets the savings derived from the application of Phesgo. In particular, the first test considers up to box 1, which includes only the monetary savings for the payer. That is, 456 457 the savings in drugs and non-drug consumables, which are equal to US\$ 90,534. We 458 find that a 3.6% decrease in the price of pertuzumab is sufficient to equal these savings.

459 The second test considers up to box 2, which adds patients' savings in indirect costs. It 460 is worth it to recall that these savings only considered measurable benefits that were 461 monetizable, which are savings in productivity. These savings were calculated in US\$ 462 209.556. In that sense, the second test consisted in finding a price of pertuzumab that 463 let us offset the US\$ 300,090 savings that are generated by boxes 1 and 2. We find that, 464 for that to happen, there must be a 11.9% decrease in the price of pertuzumab.

465 Finally, we add a referential test -test 3- to stress the fact that there is a third box of savings that no reduction in the price of pertuzumab could offset. This group of savings 466 467 contemplates non-monetary benefits both for patients and the payer. Regarding the

468 patients, there are important benefits such as: gain in comfort, gain in time for no 469 productive activities, gain in overall utility. On the other hand, for the payer, there are 470 other such benefits like: attention capacity increase, relief of overburden for nurses, 471 among others.

Fig 7. Pertuzumab price sensitivity analysis. Note: The baseline price for pertuzumab
is US\$ 1,941. There is no estimation for test 3, as it contemplates a box of non-monetary
savings.

475 **Conclusions and discussion**

As it was shown, switching from an IV to a SC treatment scheme produces significant 476 477 monetary and non-monetary savings for the healthcare system and the patient. Despite 478 this result, we estimate that the generated monetary savings allow EsSalud to afford the 479 full annual costs of only 2 additional treatments without increasing its budget. This would cover 7% of the gap of 29 patients who do not have access to full treatment without 480 increasing the budget. Moreover, by means of a univariate sensitivity analysis, it is 481 482 obtained that the price of Phesgo would have to increase by 15.83% so that the costs of 483 the two treatments are equalized and zero savings are perceived.

484 Furthermore, increasing the number of treated patients is only possible through the adoption of Phesgo instead of the current IV treatment. This is mainly because the use 485 of Phesgo decreases the amount of infrastructure and personnel required to treat each 486 patient. Otherwise, EsSalud would be required to invest in expanding the existing 487 infrastructure to be able of closing the treatment gap, due to the constraints of healthcare 488 489 resources. Therefore, even if biosimilars were to match the monetary savings of Phesgo 490 (drug and consumables costs) and monetary savings were achieved, there would be no capacity to expand the current care. 491

Additional extensions to this study may cover a deeper qualitative approach, such as the collection of patients' perceptions on which treatment increase their welfare. In the same way, we recommend future contributions to carry out the stopwatch measurement of the mixing and treatment room procedures, and the inclusion of further welfare components in the indirect costs, which we delimit to the loss of productivity. Finally, it would be relevant to test if the above conclusions are extensible to other Peruvian healthcare providers, such as the ones administered by the Ministry of health (Minsa).

499 Acknowledgments

500 We thank Rodrigo Castro for his help format this research paper for publication. His

501 contribution ensured the professional presentation of this work.

502 Author Contributions

- 503 **Conceptualization:** Miguel Figallo, María F. Delgado, Mauricio Gonzalez.
- 504 Methodology: Miguel Figallo, María F. Delgado
- 505 Validation: Miguel Figallo, María F. Delgado, Mauricio Gonzalez
- 506 Formal analysis: María F. Delgado, Mauricio Gonzalez, Adrián Arenas
- 507 **Data Curation:** Miguel Figallo, María F. Delgado, Mauricio Gonzalez, Adrián Arenas.
- 508 Writing Original Draft: Miguel Figallo, María F. Delgado, Mauricio Gonzalez.
- 509 Writing Review & Editing: Miguel Figallo, Mauricio Gonzalez, Adrián Arenas.
- 510 Visualization: Miguel Figallo, Mauricio Gonzalez.
- 511 **Supervision:** Miguel Figallo.
- 512 **Project administration:** Miguel Figallo.

513 **Funding acquisition:** Miguel Figallo.

%20de%202%2C5.

514

521

515 **References**

- 5161. EsSalud. EsSalud detectó más de 10 mil nuevos casos de cáncer de mamá,517cuello uterino, próstata, estómago, pulmón y piel durante el 2022. [Online].; 2023.518Available from: http://noticias.essalud.gob.pe/?inno-noticia=essalud-detecto-mas-de-10-mil-519nuevos-casos-de-cancer-de-mama-cuello-uterino-prostata-estomago-pulmon-y-piel-durante-el-5202022#:~:text=As%C3%AD%2C%20por%20ejemplo%2C%20los%20casos,anterior%20que%20fue
- American Cancer Society. Estado de HER2 del cáncer de seno. [Online].; 2022.
 Available from: https://www.cancer.org/es/cancer/tipos/cancer-de-seno/comprension-deun-diagnostico-de-cancer-de-seno/estado-de-her2-del-cancer-de-seno.html.
- 525 3. EsSalud. Eficacia y seguridad del uso de pertuzumab en combinación con
 526 trastuzumab y docetaxel para el tratamiento de pacientes con cáncer de mama
 527 metastásico her 2 positivo sin terapia sistémica previa. Lima: 2017.
- 528 4. Swain S, Miles D, Kim SB, Im YH, Im SA, Semiglazov V, et al. Pertuzumab,
 529 trastuzumab, and docetaxel for HER2-positive metastatic breast cancer
 530 (CLEOPATRA): end-of-study results from a double-blind, randomized, placebo531 controlled, phase 3 study. The Lancet Oncology. 2020.
- 5. Tan A, Im SA, Mattar A, Colomer R, Stroyakovskii D, Nowecki Z. Fixed dose combination of pertuzumab and trastuzumab for subcutaneous injection plus chemotherapy in HER2-positive early breast cancer (FeDeriCa): a randomized, open-label, multicentre, non-inferiority phase 3 study. The Lancet. 2021: 85-97.
- 6. O'Shaughnessy J, Sousa S, Cruz J, Fallowfield L, Auvinen P, Pulido C, et al.
 Preference for the fixed-dose combination of pertuzumab and trastuzumab for
 subcutaneous injection in patients with HER2-positive early breast cancer

539 (PHranceSCa): A randomised, open-label phase II study. Eur J Cancer. 2021:
540 223-232.

Jackisch C, Manevy F, Frank S, Roberts N, Shafrin J. White Paper on the Value
 of Time Savings for Patients and Healthcare Providers of Breast Cancer Therapy:
 The Fixed-Dose Combination of Pertuzumab and Trastuzumab for
 Subcutaneous Injection as an Example. Advances in Therapy. 2022.

- Lopez-Vivanco, Salvador, Diéz, López, De Salas-Cansado, Navarro, et al. Cost
 minimization analysis of treatment with intravenous or subcutaneous
 trastuzumab in patients with HER2-positive breast cancer in Spain. 2017.
- Soriano Garcia JL, Concepción IR, Mora Díaz I, Fernández Hernández I, Batista
 Albuerne N, Vilaragut García M, et al. Minimización de costos de aplicación
 subcutánea o intravenosa de trastuzumab y pertuzumab en pacientes con
 cáncer mamario. 2021.
- 55210. EsSalud. Resumen de Presupuesto Analítico de Personal. [Online].; 2019.553Availablefrom:
- http://www.essalud.gob.pe/transparencia/pdf/informacion/resumen_de_presupuesto_analitic
 o_2019.pdf.
- 11. Instituto Nacional de Salud. Pertuzumab, trastuzumab y quimioterapia como
 primera línea de tratamiento para el cáncer de mama HER2+ metastásico o
 localmente avanzado irresecable en adultos con estado funcional ECOG 0-2.
 Lima: 2023.
- 560 12. Seminario B. Estimación del costo social por fallecimiento prematuro. Lima:
 561 Ministerio de Economía; 2017.
- 13. Instituto Nacional de Enfermedades Neoplásicas. Documento Tecnico Manejo
 Multidisciplinario Neoadyuvante/Adyuvane del Cáncer de Mama HER2 (+) y
 Triple Negativo. Lima: 2019.

- 565 14. Instituto Nacional de Estadística e Informática. Enaho. [Online].; 2022. Available
- 566 from: https://www.datosabiertos.gob.pe/dataset/encuesta-nacional-de-hogares-enaho-2022-
- 567 instituto-nacional-de-estad%C3%ADstica-e-inform%C3%A1tica-%E2%80%93

Intravenous treatment	Subcutaneous treatment during chemotherapy cycles (first 6 cycles)	Subcutaneous treatment without chemotherapy cycles (last 12 cycles)
Evaluation and installation	Evaluation and installation	Evaluation and installation
Intravenous cannulation	Intravenous cannulation	
Hydration and premedication	Hydration and premedication	
Mixing room preparation	Mixing room preparation	
Pertuzumab administration		
Post pertuzumab monitoring	Phesgo SC administration	Phesgo SC administration
Trastuzumab administration	Post Phesgo SC monitoring	Post Phesgo SC monitoring
Post trastuzumab monitoring		
Docetaxel administration	Docetaxel administration	The application of Phesgo presents
		and in the terms of time and in the second second













